Stocks · Health care · Biological Products, (No Diagnostic Substances)

Immunovant, Inc.

IMVT Clue Score35
United States Fiscal year ends March CIK 0001764013 Results filed 6 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Roivant Sciences Ltd.
12 Dec 2025
Director
Buy
16,666,666
$21.00
$350.00M
Roivant Sciences Ltd.
13 Jan 2025
Director
Buy
16,845,010
$20.00
$336.90M
Roivant Sciences Ltd.
2 Oct 2023
Director
Buy
1,526,316
$38.00
$58.00M
Roivant Sciences Ltd.
6 Oct 2022
10% owner
Buy
416,667
$6.00
$2.50M
Atul Pande
30 Sep 2022
Director
Buy indirect
15,000
$5.60
$84.00K
Frank Torti
29 Sep 2022
Director
Buy
20,000
$5.81
$116.20K
Showing 250 of 298 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 324
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 18
Sales straight out of an exercise 10
Sales at will 231
Transactions with no price 0
Shares from compensation/vesting 84,422,925
Sales filed before the plan box existed 33
History held since 15 May 2019